Authors
Latest:
Dr Kareff on the Utility of ADCs in NSCLCSamuel Kareff, MD, MPH, discusses the treatment of patients with non–small cell lung cancer.
Latest:
Dr. Melosky on the Use of Lurbinectedin in SCLCBarbara Melosky, MD, FRCPC, discusses the use of lurbinectedin in small cell lung cancer.
Latest:
Dr Hathaway on the Investigation of Distress on the TME in Ovarian CancerCassandra A. Hathaway, MD, discusses the rationale for investigating the association between distress, such as depression, and the tumor immune microenvironment in patients with ovarian cancer.
Latest:
Dr Chuong on the Patterns of Guided Radiation Therapy in Pancreatic CancerMichael Chuong, MD, FACRO, discusses patterns of locoregional recurrence following guided radiation therapy in pancreatic cancer.
Latest:
Dr Coombs on Notable BTK Inhibitor Combination Studies in CLLCallie Coombs, MD, discusses the investigation of notable BTK inhibitor combination trials in patients with chronic lymphocytic leukemia.
Latest:
Dr Brohl on the Safety and Efficacy of IFx-Hu2.0 in MCC and CSCCAndrew S. Brohl, MD, discusses the safety and immunologic responses with intratumoral administration of Idx-Hu2.0 in patients with advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma.
Latest:
Dr. Arnaoutakis on the ADAURA Trial Examining Osimertinib in EGFR-Mutant Lung CancerKonstantinos Arnaoutakis, MD, discusses the phase 3 ADAURA trial examining osimertinib in the adjuvant treatment of patients with EGFR-mutant lung cancer.
Latest:
Dr. Au on the Results of a Subgroup Analysis Evaluating Antibody Response to COVID-19 in CancerLewis Au, MBBS, BMedSci, FRACP, discusses the results of a subgroup analysis evaluating antibody responses to COVID-19 in patients with cancer.
Latest:
Dr Das on the Use of Neoadjuvant and Adjuvant Chemoimmunotherapy Regimens in NSCLCDevika Das, MD, MSHQS, discusses the use of neoadjuvant and adjuvant chemoimmunotherapy for patients with resectable non–small cell lung cancer, and emphasizes the importance of multidisciplinary collaboration when incorporating these regimens into treatment approaches.
Latest:
Dr. Stenzl on Future Research With Enzalutamide in Prostate CancerArnulf Stenzl, MD, discusses future research efforts with enzalutamide in prostate cancer.
Latest:
Dr. Tagawa on the Evolution of ADCs in mCRPCScott Tagawa, MD, MS, FACP, discusses the evolution of antibody-drug conjugates in metastatic castration-resistant prostate cancer, as well as potential future targets for ADC development in this space.
Latest:
Dr Pellini on the Clinical Utility of ctDNA Assays in NSCLCBruna Pellini, MD, discusses the utility of circulating tumor DNA assays in non–small cell lung cancer.
Latest:
Dr Hasan on the Preclinical Efficacy of ROR1-Specific CAR T-Cells in CLLMd Kamrul Hasan, PhD, discusses the preclinical efficacy and safety of ROR1-specific CAR T-cells in a preclinical mouse model of chronic lymphocytic leukemia.
Latest:
Dr Kulasinghe on a Study Profiling the NSCLC Tumor MicroenvironmentArutha Kulasinghe, PhD, discusses findings from a study profiling the tumor microenvironment of non–small cell lung cancer, as well as future directions planned with this research and the implications of these findings.
Latest:
NSCLC: Final ThoughtsThe discussion about the evolution of precision medicine in non–small cell lung cancer (NSCLC) ends as each expert discusses their final thoughts.
Latest:
Dr Obeng-Gyasi on Breast Cancer Mortality Rates in Resource-Poor NeighborhoodsSamilia Obeng-Gyasi, MD, MPH, discusses breast cancer mortality rates in resource-poor neighborhoods.
Latest:
Dr. D'Agostino on Factors for Unsustained MRD Negativity in Multiple MyelomaMattia D'Agostino, MD, discusses factors that could lead to unsustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma who are transplant eligible.
Latest:
Mentoring Oncologists in the Era of Social DistancingMentoring is critically important to the development of young academic hematology/oncology trainees.
Latest:
Dr. Patil on Unmet Needs With the Use of Immunotherapy in NSCLCPradnya D. Patil, MD, FACP, discusses unmet needs that remain to be addressed with the use of immunotherapy in patients with non–small cell lung cancer.
Latest:
Dr. Goldkorn on the Methods Used to Predict Chemotherapy Benefit in Bladder CancerAmir Goldkorn, MD, discusses the methods utilized to predict chemotherapy benefit in bladder cancer.
Latest:
Dr. Moreira on Launching the Global COVID-19 Observatory and Resource Center for Childhood CancerDaniel Moreira, MD, discusses the rationale for launching the Global COVID-19 Observatory and Resource Center for Childhood Cancer.
Latest:
Dr McLellan on the Association Between A Skin Bacterium and Severe Acute Radiation DermatitisBeth N. McLellan, MD, discusses the use of a low-cost, topical treatment to prevent severe cases of acute radiation dermatitis potentially caused by the skin bacterium Staphylococcus aureus in breast cancer.
Latest:
Dr Das on the Landscape of Current and Emerging ADCs in SCLCMillie Das, MD, discusses the current landscape of new and emerging ADCs under investigation in small-cell lung cancer and highlights the phase 2 SWOG S1929 study.
Latest:
Dr. Schmid on Next Steps for the RACE IT Trial in Urothelial CarcinomaSebastian C. Schmid, MD, discusses the future of the phase 2 RACE IT trial in urothelial carcinoma.
Latest:
Dr Biachi on the Growing Treatment Landscape in HCCTiago Biachi, MD, PhD, discusses the growing treatment landscape for patients with hepatocellular carcinoma.
Latest:
Women in Oncology: Leukemia Therapies in Humans, for HumansJudith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..
Latest:
Franklin on Strategies to Ameliorate the Effect of Social Determinants on CRC Screening RatesIsabelle Franklin, discusses strategies healthcare providers can implement to address or ameliorate disparities in place that are affecting screening rates in colorectal cancer.
Latest:
Dr Anders on the Investigation of CCR4 Antagonists in Advanced CancersRobert Albert Anders, MD, PhD, discusses the rationale for developing CCR4 antagonists for use in patients with advanced cancers, including lymphoma and non–small cell lung cancer.
Latest:
Future Management of Chronic Myeloid LeukemiaClosing out their discussion on the management of chronic myeloid leukemia, experts share practical advice and excitement for novel strategies.
